MPLT

MapLight Therapeutics, Inc.

• Seeking Alpha·3d ago

  MapLight co-founder is joint winner of 2026 Nobel Prize in Medicine

• Dow Jones·3d ago

  MapLight Therapeutics Initiated at Neutral by Guggenheim

• Benzinga·3d ago

  Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

• Dow Jones·3d ago

  Press Release: MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

• TipRanks·4d ago

  MapLight Therapeutics initiated with a Neutral at Guggenheim

• Dow Jones·09/29 17:54

  MapLight Therapeutics Currently Down 11 Consecutive Days, on Pace for Record Losing Streak -- Data Talk

• Dow Jones·09/24 16:56

  MapLight Therapeutics on Track for Record Losing Streak -- Data Talk

• Simply Wall St·09/18 17:48

  We Think MapLight Therapeutics (NASDAQ:MPLT) Needs To Drive Business Growth Carefully

• Benzinga·09/09 21:34

  MapLight Therapeutics Files Prospectus Related To The Resale Of Up To 13,181,055 Common Shares By Selling Stockholders

• TipRanks·09/09 21:30

  MapLight Therapeutics files to sell 13.18M shares of common stock for holders

• TipRanks·08/31 11:15

  MapLight Therapeutics price target lowered to $43 from $45 at Needham

• Dow Jones·08/31 10:15

  MapLight Therapeutics Is Maintained at Buy by Needham

• Dow Jones·08/31 10:15

  MapLight Therapeutics Price Target Cut to $43.00/Share From $45.00 by Needham

• Benzinga·08/31 10:05

  Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

• TipRanks·08/19 02:07

  Major Investor Makes Bold Move on MapLight Therapeutics Stock